Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | ALPI | P09923 | 1/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 5/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 5/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 5/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.36 |
| ▸ | USP2 | O75604 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | RGS12 | O14924 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28669915 | 1.00 | SLC7A5 (0.38) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL4262731 | 0.84 | SLC7A5 (0.40) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL7200971 | 0.83 | SLC7A5 (0.39) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL27590645 | 0.82 | SLC7A5 (0.39) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL1614571 | 0.82 | SLC7A5 (0.38) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL29436333 | 0.82 | SLC7A5 (0.38) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL28679240 | 0.82 | SLC7A5 (0.39) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL229096 | 0.82 | SLC7A5 (0.38) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL3284389 | 0.82 | SLC7A5 (0.38) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL30264845 | 0.81 | SLC7A5 (0.37) | SLC7A5PKMPTGS1ALPIXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025081231-A1 | INHIBITORS AND USES THEREFOR | Infensa Bioscience Pty Ltd (AU) | 2025-04-24 | — | — | WO | disclosed |
| EP-4416282-A1 | PROTEINACEOUS MOLECULES AND USES THEREFOR | The University of Queensland (AU) | 2024-08-21 | — | — | EP | disclosed |
| US-12018060-B2 | Glucagon derivatives | HANMI PHARM CO., LTD. (KR) | 2024-06-25 | — | — | US | disclosed |
| US-11872283-B2 | Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof | HANMI SCIENCE CO., LTD (KR) | 2024-01-16 | — | — | US | disclosed |
| US-11739121-B2 | EPHA2 agonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230220034-A1 | METHOD FOR IMPROVING SOLUBILITY OF PROTEIN AND PEPTIDE BY USING IMMUNOGLOGULIN FC FRAGMENT LINKAGE | HANMI PHARM. CO., LTD (KR) | 2023-07-13 | — | — | US | disclosed |
| WO-2023077188-A1 | PROTEINACEOUS MOLECULES AND USES THEREFOR | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023060319-A1 | PROTEINACEOUS MOLECULES AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023056527-A1 | PROTEINACEOUS MOLECULES AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2023-04-13 | — | — | WO | disclosed |
| EP-2884994-B1 | COMPOSITION FOR TREATING HYPERLIPIDEMIA COMPRISING OXYNTOMODULIN DERIVATIVE | HANMI PHARM IND CO LTD (KR) | 2023-01-18 | — | — | EP | disclosed |
| US-5672585-A | HYDROPHOBIC AND CATIONIC AMINO ACID-CONTAINING CYCLIC (POLY)PEPTIDES HAVING HIGH AFFINITY FOR GLYCOPROTEIN IIB/IIIA RECEPTORS TO INHIBIT PLATELET AGGREGATION WITHOUT PROLONGED BLEEDING | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1997-09-30 | — | — | US | disclosed |
| EP-0527798-B1 | METHOD AND COMPOSITION FOR TREATING THROMBOSIS | JOLLA CANCER RES FOUND (US) | 1997-07-16 | — | — | EP | disclosed |
| US-5648330-A | Method and composition for treating vascular graft occlusion | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1997-07-15 | — | — | US | disclosed |
| EP-0749979-A2 | Method and composition for treating thrombosis | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1996-12-27 | — | — | EP | disclosed |
| EP-0705274-A1 | METHOD AND COMPOSITION FOR TREATING THROMBOSIS | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1996-04-10 | — | — | EP | disclosed |
| US-5493007-A | OLIGOPEPTIDE | GENENTECH, INC. (US) | 1996-02-20 | — | — | US | disclosed |
| WO-1995000544-A1 | METHOD AND COMPOSITION FOR TREATING THROMBOSIS | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1995-01-05 | — | — | WO | disclosed |
| EP-0527798-A1 | METHOD AND COMPOSITION FOR TREATING THROMBOSIS. | JOLLA CANCER RES FOUND (US) | 1993-02-24 | — | — | EP | disclosed |
| WO-1992017492-A1 | PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIII¿a? | GENENTECH, INC. (US) | 1992-10-15 | — | — | WO | disclosed |
| WO-1991015515-A1 | METHOD AND COMPOSITION FOR TREATING THROMBOSIS | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1991-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739121-B2 | EPHA2 agonists and uses thereof | EPHA2, EPHB2, EPHA6 | SLC7A5 3830/4885PKM 2804/4885PTGS1 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.